Terapia Génica del Cáncer
TGC
Hospital of the University of Pennsylvania
Filadelfia, Estados UnidosPublicacións en colaboración con investigadores/as de Hospital of the University of Pennsylvania (2)
2021
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501
2020
-
Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial
Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317